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Abstract  
Background 
Plantar pressures are commonly used as clinical measures, especially to determine optimum foot 
orthotic design. In rheumatoid arthritis (RA) high plantar foot pressures have been linked to 
metatarsophalangeal (MTP) joint radiological erosion scores. However, the sensitivity of foot 
pressure measurement to soft tissue pathology within the foot is unknown. The aim of this study 
was to observe plantar foot pressures and forefoot soft tissue pathology in patients who have RA. 
Methods   
A total of 114 patients with established RA (1987 ACR criteria) and 50 healthy volunteers were 
assessed at baseline. All RA participants returned for reassessment at twelve months. Interface 
foot-shoe plantar pressures were recorded using an F-Scan® system. The presence of forefoot 
soft tissue pathology was assessed using a DIASUS musculoskeletal ultrasound (US) system. 
Chi-square analyses and independent t-tests were used to determine statistical differences 
between baseline and twelve months. Pearson’s correlation coefficient was used to determine 
interrelationships between soft tissue pathology and foot pressures. 
Results 
At baseline, RA patients had a significantly higher peak foot pressures compared to healthy participants 
and peak pressures were located in the medial aspect of the forefoot in both groups.  In contrast, RA 
participants had US detectable soft tissue pathology in the lateral aspect of the forefoot. Analysis of 
person specific data suggests that there are considerable variations over time with more than half the RA 
cohort having unstable presence of US detectable forefoot soft tissue pathology. Findings also indicated 
that, over time, changes in US detectable soft tissue pathology are out of phase with changes in foot-shoe 
interface pressures both temporally and spatially. 
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Conclusions  
We found that US detectable forefoot soft tissue pathology may be unrelated to peak forefoot 
pressures and suggest that patients with RA may biomechanically adapt to soft tissue forefoot 
pathology. In addition, we have observed that, in patients with RA, interface foot-shoe pressures 
and the presence of US detectable forefoot pathology may vary substantially over time. This has 
implications for clinical strategies that aim to offload peak plantar pressures. 
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Background 
Patients with rheumatoid arthritis (RA) present with pain, changes in gait, foot deformity and 
restrictions in the choice of footwear [1-4]. This has led to the development of guidelines for the 
assessment and management of foot complications associated with RA. Annual foot health 
screening is recommended with the aim of identifying changes in foot health and monitoring foot 
health interventions [5, 6]. However, in a recent study of patients with RA we demonstrated that 
a high percentage of soft tissue pathology within the forefoot detectable by musculoskeletal 
ultrasound (US) was often missed by clinical examination [7]. In addition, we found that US 
detectable soft tissue pathology within the forefoot was clinically relevant but varied in 
prevalence over time and hypothesised that this was not necessarily due to RA disease but 
potentially associated with mechanical factors [8]. 
 
Measurement of foot-shoe interface pressures is increasingly used in clinical practice to determine 
clinical interventions, such as foot orthoses, for patients with RA, yet there is very little evidence for 
this practice over time. In cross-sectional studies peak plantar pressures are most often reported and 
evidence shows the forefoot as the region with the highest peak plantar pressures [9-14]. Notably, 
the clinical relations of plantar pressures in RA patients are less well understood. Some have 
attempted to address this using radiographic erosion scores that show associations of MTP joint 
erosions with peak plantar foot pressures [11, 13, 15]. A main criticism of the radiological 
erosion scores is that they only give information on prevalent joint damage and are insensitive to 
RA soft tissue changes [16, 17]. We therefore decided to investigate patterns of foot-shoe 
interface pressures and presence of US detectable soft tissue pathology in a cohort of RA 
participants at two time points, baseline and twelve months.  
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Methods 
The optimal research design was considered to be a longitudinal cohort study in which the foot pathology 
and foot pressure characteristics of a heterogenous group of patients who have RA were assessed at two 
time points. The use of two cross sectional time points within the same population allows for better 
understanding of the effect of variability in pathophysiology of RA within the foot over time. Embedded 
within the design of study was a case reference study, to enable comparisons of baseline demographic and 
clinical characteristics of the RA study sample with healthy control participants.  
 
Approval for the study was obtained from the Southampton and South West Hampshire research 
ethics committee for the RA participants and the Faculty of Medicine, Health and Life Sciences, 
University of Southampton Research ethics committee for the healthy participants. All 
participants gave informed written consent prior to participation.  
 
Study population 
The study population consisted of a consecutive sample of 114 RA patients who attended the 
Rheumatology Department at Southampton General Hospital. Data collection took place in the 
Wellcome Trust Clinical Research Facility, Southampton General Hospital, between August 
2006 and December 2008. These individuals were participants in the RA Feet Ultrasound project 
(FeeTURA), a prospective cohort study designed to investigate the epidemiology of forefoot 
pathology in RA patients. The point of entry into FeeTURA included all patients who have RA 
who were attending for routine rheumatological clinical care during the recruitment period (April 
2006 – April 2007). Previous publications have described the high prevalence of forefoot bursal 
hypertrophy in this patient group [7, 8]. The present analysis was conducted to examine foot 
pressure outcomes in a subgroup of the FeeTURA project participants. 
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To be eligible for participation in the parent FeeTURA study, participants had to be over the age 
of eighteen and have a positive diagnosis of RA as defined by the previous American College of 
Rheumatology (ACR) 1987 criteria [18]. Patients were excluded from the study if they had a 
history of previous forefoot surgery, received a corticosteroid injection to the forefoot within the 
three months prior to this study, had an additional musculoskeletal disease (e.g. primary 
osteoarthritis, gout, Paget’s, systemic lupus erythematosus), or had a serious medical (other than 
RA) or psychological disorder that would prevent completion of the study protocol. Also, for this 
foot pressure study, individuals who could not walk five metres were excluded.  
 
A total of 149 patients were recruited into the parent FeeTURA study and assessed at baseline 
(start of the study). The number dropped to 120 who were re-assessed at twelve months due to 
non-responses (n=21), death (n=1), illness (n=6) and non-eligibility based on an inability to walk 
five metres (n=1). During the pre-selection process for this investigation, data from a further 6 
subjects that were mal-recorded at either baseline or twelve months were excluded from the final 
analyses. 
 
A gender matched healthy comparison group was recruited from the students and staff of the 
University of Southampton and assessed at the start of the study at baseline only. The inclusion 
criteria were an age of 18 + years, no positive diagnosis of an inflammatory arthropathy and all 
participants had to fulfill the same exclusion criteria as those for the RA group. Fifty healthy 
participants (37 female, 12 male; mean age 33.2 years, range 19-61; mean weight 74 kg, range 
54.5-120) were recruited and plantar pressure measurements and ultrasound data subsequently 
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recorded. Participants were instructed to attend the visit wearing comfortable flat shoes that they 
wore the most at the time.  
 
Assessment of demographic and clinical characteristics of the RA participants 
Demographic data including age, gender, weight, height, disease duration and presence of 
rheumatoid factor was recorded.  Information regarding current medication including Disease 
Modifying Anti-Rheumatic Drug (DMARD) use was obtained from the patients’ clinical notes. 
C-reactive protein (CRP) and Erythrocyte Sedimentation Rate (ESR) values were obtained from 
the clinical/laboratory database. Clinical activity of RA disease was assessed by the disease 
activity score 28 tender and swollen joint count (DAS28-ESR) [19] and was obtained from the 
patients’ clinical notes within one month of the visit. 
 
All foot assessments were conducted by a single investigator (CB) at both time points and 
followed recommended guidelines for clinical assessment [5, 6]. This included observation of the 
presence of foot deformities: hallux abducto valgus (HAV), 5th metatarsophalangeal (MTP) joint 
exostosis, lesser toe deformity, MTP joint subluxation, pes cavus and pes planus.  Motion at the 
ankle, sub-talar, mid-tarsal and first MTP joints were assessed and classified as full motion, 
limited motion or rigid according to clinical guidelines [5, 6]. Information regarding use of foot 
orthotic devices, presence of foot ulceration and access to clinical foot services was also 
recorded.  
 
Footwear was assessed and categorised as either prescribed therapeutic footwear or retail (shop 
bought) footwear. Footwear was further noted as being suitable or not suitable according to fit 
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and style (e.g. court styles and high heel/stiletto shoes were deemed unsuitable). Due to the high 
numbers of participants and the highly emotive factors associated with both prescribed 
therapeutic and retail footwear [4, 20, 21] it was neither economically feasible nor clinically 
desirable to standardise footwear between visits. Participants were instructed to attend each visit 
wearing comfortable flat shoes that they wore the most at the time.  
 
Both subscales of the Leeds Foot Impact Scale Questionnaire (LFIS), impairment/footwear 
(LFISIF) and activity limitation/participation restriction (LFISAP) previously validated for use in 
RA populations [22] were used to identify patient reported foot impact.  LFISIF contains twenty 
one items related to foot pain and joint stiffness, as well as footwear related impairments with a 
total score range 0 -21. LFISAP contains thirty items related to activity limitation and 
participation restriction with a total score range 0-30 [22]. Responses to each question are 
dichotomized as yes or no and scoring is a simple tally for each domain [22] with 4 or less 
suggested to represent good foot health and scores higher than 4 representing poor foot health  
[23]. 
 
 
Foot pressure measurement 
A portable pressure measurement device, the FScan® in-shoe system, (Tekscan Inc. USA) was 
used to record foot-shoe interface pressures. The FScan® system has recently been demonstrated 
as highly reliable and suitable for measurement of plantar foot pressures in RA patients in 
clinical practice [24]. The system is calibrated to weight and uses Force Sensing Resistor (FSR) 
technology to enable dynamic, real time measurement to measure the interface between the foot 
and footwear. The instrumented insole is composed of 960 Sensing Elements/Foot (Sensels), 
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each 0.15mm in thickness with a density of four sensors per cm2. It was trimmed to fit footwear 
so that it did not interfere with either walking, comfort or fit of footwear (FScan® system 
features, Tekscan US).  
 
A predetermined walkway of approximately five metres was established along the length of the 
clinical room. Each participant was initially asked to walk the length of the walkway to 
familiarise themselves with the protocol and become accustomed to the cables. All participants 
were asked to walk with their own footwear in a straight line at a comfortable walking speed, 
away from the FScan® system so that any cable trip hazard was avoided. An identical standard 
recommended protocol was followed for each participant to minimise variations in recordings.  
 
The data acquisition parameters were prescribed to record 10 seconds of information with a 
165Hz sampling frequency. The FScan® system automatically records the individual data from 
all of the sensors and estimates the pressure distribution on the plantar aspect of the feet during 
each footstep, storing data on the system for later analysis. 
 
F-Scan® sensors are marketed as re-useable and previous laboratory work has identified sensor 
life-spans of 40 trials over ten metres [25]. However, we are aware of reported limitations of the 
FScan® pressure measurement system employed, especially the reliability of the sensors has 
been questioned [9, 26]. Therefore, we conducted a repeated measures same subject study to test 
reliability of the sensors for clinical use. Our findings suggested that there was a trend in the loss 
of FScan® sensor lifespan following multiple clinical uses after 20 trials. To minimise the 
variation and inaccuracy of data recordings we adopted a strict protocol as follows:  
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i. The sensors were placed within the participants’ footwear with the backing intact to 
minimise damage as recommended [25]. 
ii. Each time a sensor in our study was used the participant code, number of ‘walks’and 
number of steps taken was noted on the sensor log sheet. 
iii. Sensors were discarded after maximum use of 20 times (over five metres) or if physical 
damage to the sensor was observed.  
iv. In addition, with careful recalibration of sensors at each trial and observation of the 
walking trials, any mal-recordings were identified and excluded from the final data 
analysis. 
 
The FScan® system was set to automatically discard the first and last footsteps. The third 
footstep was selected for analysis as this was considered representative of mid-gait and peak 
pressures were calculated. Using the FScan® standard masking software, the footprints were 
divided into six segments, A (lateral-forefoot, ie. 3rd to 5th MTP joints), B (medial-forefoot, ie.1st 
to 2nd MTP joints), C (lateral-midfoot), D (medial-midfoot), E (lateral-rearfoot), F (medial-
rearfoot).  The location (ie. segment A, B, C, D, E or F) was noted in which the peak pressure of 
the footstep was identified.  
 
To determine relations in locations of US detectable forefoot pathology and location of peak 
pressure, cases in which the peak pressure was displayed within the forefoot as either medially 
dominant (segment B) or laterally dominant (segment A) were selected for analysis. 
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Ultrasound assessments 
All US scans were performed immediately after the clinical foot examinations and foot pressure 
measurements by a single investigator (CB). We attempted to reduce the effect of investigator 
bias by maintaining a systematic order to the data collection and using experienced independent 
data handlers to double enter and clean all the information onto the data sheet.  
 
A Diasus ultrasound system (Dynamic Imaging Ltd, UK) was used to image the forefoot of both 
feet to determine the presence of forefoot pathology (MTP joint synovial hypertrophy and 
erosion and plantar forefoot bursal hypertrophy). The Diasus ultrasound system (Dynamic 
Imaging Ltd. Scotland UK) operates as a system with dual probe of which we employed the 8-
16MHz, footprint 26mm, for dorsal scans and the 5-12MHz linear probe, footprint 40mm, for 
plantar scans. Scanning was in B-Mode and recorded according to standard guidelines for MTP 
joint pathology [27] and previous recommendations for detection of plantar forefoot bursal 
hypertrophy [28]. Good image acquisition and interpretation agreement (kappa 0.702; p<0.01) 
with an expert US radiologist was confirmed prior to data collection [28].  
 
The presence or absence of MTP joint synovial hypertrophy and erosion was recorded in the first 
to fifth MTP Joints. The presence or absence of forefoot bursal hypertrophy was recorded in the 
intermetatarsal (IM) spaces 1/2, 2/3, 3/4, 4/5 and the sub-metatarsal (SM) head areas 1 – 5. 
Locations of forefoot pathology were allocated as A (lateral-forefoot, ie. 3rd to 5th MTP joints 
including IM spaces 3/4 and 4/5, SM areas 3,4,5) or B (medial-forefoot, ie.1st to 2nd MTP joints, 
including IM spaces 1/2 and 2/3, SM areas 1,2) (Figure 1).  
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To facilitate analysis for associations, the scores for US detectable pathology presence were 
summated as follows:  
Segment A (Lateral): presence of MTP joint synovial hypertrophy 3, 4 and 5 + presence of MTP 
joint erosion 3, 4 and 5 + presence of forefoot bursal hypertrophy IM 3/4, 4/5, SM 3, 4, 5. 
Segment B (Medial): presence of MTP joint synovial hypertrophy 1, 2 + presence of MTP joint 
erosion 1, 2 + presence of forefoot bursal hypertrophy IM 1/2, 2/3, SM 1, 2. 
 
Analysis 
Using prior data [10] for normally distributed matched pairs with peak pressure as the primary 
outcome, power calculations indicated that the sample size of 114 for 90% power was more than 
adequate to detect differences in outcomes of pathology and peak plantar pressures. All data 
analyses were conducted using Statistical Package for the Social Sciences (SPSS) version 17.0 
software (SPSS, Chicago IL). Unless otherwise noted, a p value of less than 0.05 was considered 
the critical level to determine statistical significance.  
 
The analyses mainly focused on descriptive changes in the presence and location of US 
detectable forefoot pathology and value and location of peak pressure at baseline for both RA 
and healthy participants and after a period of twelve months for RA participants only. 
Demographic and clinical characteristic information is presented as mean and standard 
deviations (+/-SD). The foot specific characteristics of the study participants are presented as 
frequencies of occurrence and graphically as bar charts. Chi-square (χ2) analyses were used to 
determine differences within location of peak pressures between RA and healthy participants at 
baseline and for RA participants with location of peak pressures and location of forefoot 
pathology from baseline to 12 months. Chi-square (χ2) analyses were also used to determine 
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differences in peak pressure values and locations according to footwear type of the RA 
participants at baseline and twelve months.  
 
Independent sample t-tests were used to determine differences between peak pressure values for 
RA and control participants and paired t-tests were used to determine differences for peak pressure 
values for the RA participants from baseline to twelve months. Change in the demographic and 
clinical variables was calculated as person specific data and is presented as frequencies.  
 
Pearson’s correlation coefficient was used to determine interrelationships between the US 
detectable pathology and values of peak pressure within each forefoot segment at baseline and at 
12 months, as well as between the changes in forefoot pathology and changes in peak pressure 
values after 12 months. The distribution of data for both peak pressures and US detectable forefoot 
pathology were found to be approximately normal, justifying the use of a parametric method for 
assessing correlation. 
 
 
Results 
RA participant demographics 
One hundred and fourteen patients (93 female and 21 male; 22 seronegative, 89 seropositive, 3 
missing data) were included the study. The mean age of the RA participants was 59.6 years 
(SD:12.0; range: 25-87) and mean disease duration was 11.8 years (SD: 10.3; range 0.6-43) at 
baseline start of the study. The group of RA participants were heterogeneous as can be seen by 
the clinical and demographic variables for baseline and twelve months (Table 1). Analysis of 
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group means showed no significant change over the 12 month period for all variables. However 
when person specific data was calculated it is notable that change had taken place over the 
twelve month period with almost equal numbers of participants increasing as decreasing for each 
variable. 
 
Pharmacological treatment appeared to be stable within the group. At baseline the participants’ 
regular treatment of RA included 66% (n=75) taking methotrexate and 47% (n=53) taking anti-
TNFα (Adalimumab, Infliximab, Etanercept) therapy. At 12 months the participants’ regular 
treatment of RA included 71% (n=81) taking methotrexate and 46% (n=52) taking anti-TNFα 
(Adalimumab, Infliximab, Etanercept) therapy.  
 
RA participant clinical foot characteristics 
Patient reported foot impact appears high with mean impairment/footwear scores of 10.6/21 
(baseline) and 10.3/21 (twelve months) and mean activity limitation/participation restriction 
16.5/30 (baseline) and 16.6/30 (twelve months) (Table 1). Analysis of person specific data shows 
that both scores changed over the twelve month period with almost equal numbers of participants 
experiencing an increase in foot impact as those experiencing a decrease (Table 1). 
 
A high percentage of symmetrical foot deformity was observed for HAV, 5th MTP joint 
exostoses, lesser toe deformities, MTP joints 1-5 subluxation and pes plano valgus foot position 
at both baseline and 12 months (Figure 2). From figure 3, the highest proportion of participants 
had limited ranges of motion in their foot joints at both time points. 
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At baseline 56% (n=64) had recorded foot symptoms in their clinical notes, 61% (n=70) had seen 
a chiropodist or podiatrist but only 31% (n=35) were currently receiving clinical foot care on a 
regular basis. No participants had recorded presence of foot ulceration although 7% (n=8) 
reported a previous history of foot ulceration. Access to clinical foot care appeared to have 
improved slightly at 12 months with 42% (n=48) receiving clinical foot care on a regular basis. 
Foot ulceration was noted in 2% (n= 2) at twelve months.  
 
At baseline 97% (n=111) wore retail shoes and 3% (n=3) wore prescribed therapeutic shoes. Of 
the retail shoes, 16% (n=18) were deemed unsuitable by the podiatrist.  At 12 months 93% 
(n=106) wore retail shoes and 6% (n=7) wore prescribed therapeutic shoes. Of the retail shoes, 
6% (n=7) were deemed unsuitable by the podiatrist.  At baseline 11% (n=12) wore simple 
insoles, 4% (n=5) wore moulded insole devices and 3% (n=3) wore total contact foot orthoses.  
Slightly more wore simple insoles (15%, n=17), moulded insole devices (6%, n=7) and total 
contact foot orthoses (4%, n=5) at twelve months. 
 
 
Foot pressure characteristics (RA participants and healthy controls) 
Peak pressure values within the whole footstep were significantly different at baseline between 
the RA participants and the group of healthy control participants (Table 2).  To assess whether 
these differences could be due to the confounding influences of age and weight, an analysis of 
variance (ANOVA) was performed. After adjustment for age and weight the results remained 
significant (p<0.001).  
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No significant differences were found in peak pressure values for the RA participants from 
baseline to 12 months (Table 3). However when person specific data was calculated it is notable 
that change had taken place over the twelve month period with almost equal numbers of 
participants having an increase (left 47%, right 47%) in peak foot pressure as those who had a 
decrease (left 53%, right 54%). 
 
Once the footprint was segmented into the six components, the majority of RA participants 
displayed peak pressure values within the forefoot region (ie. segments A and B) in both feet 
(Table 4, Figure 4). At baseline no significant differences were found in the locations of the peak 
pressures between the RA participants and the group of healthy control participants (left 
χ
2
=0.185, df=1, p=0.185 or right feet χ2 =0.004, df=1, p=0.947). 
 
When the locations of peak pressures were analysed for the RA participants at baseline and 
twelve months significant differences were found for both left (χ2 =12.063, df=1, p=0.001) and 
right feet (χ2 =4.627, df=1, p=0.031).  Further analysis of person specific data showed that peak 
pressure location was stable in only 61% (n=69) of participants in the right foot and only 34% 
(n=39) in the left foot (Table 5). This suggests that, in RA patients, whilst the location of peak 
foot pressures is predominantly within the medial aspect of the forefoot, this may change over 
time.  
 
US detectable forefoot pathology (RA participants) 
Frequency of the presence of US detectable forefoot pathology was high. When categorized as 
medial (segment B) or lateral (segment A), the presence of MTP joint erosions appeared to be 
predominantly lateral. MTP joint synovial hypertrophy appeared to be predominantly lateral at 
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baseline, but was different at twelve months being predominantly medial.  Plantar forefoot bursal 
hypertrophy has been reported previously in the parent FeeTURA study [7, 8] and in this sub 
analysis was also predominantly lateral at both baseline and twelve months (Table 6). 
 
When person specific changes were analysed, MTP joint erosion accounted for the least change 
in status and location and thus the most stable pathology whilst just under half of participants 
were observed to have a stable status and location of MTP joint synovial hypertrophy and 
forefoot bursal hypertrophy (Table 7). This suggests that the pattern of presence of MTP joint 
synovial hypertrophy and forefoot bursal hypertrophy within the forefoot is variable in over half 
our participants. 
 
Correlations of US detectable forefoot pathology and peak forefoot pressure values 
Following the trend observations, the data was explored further to determine any significant 
associations between the presence of US detectable pathology and peak pressure values in each 
of the forefoot segments. Findings showed that there was a significant negative correlation 
between the presence of US detectable pathology and peak pressure values in the right foot 
lateral segment at follow up (PCC= -0.412, p=0.046), but this only demonstrates borderline 
significance at the 5% level, and care should be taken when inferring from this level of evidence. 
No other significant associations were found in any of the other variables. The data was explored 
further to determine any significant associations between the changes of US detectable pathology 
and changes in peak pressure values. No other significant associations were detected. 
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Discussion 
This investigation is considered the first to identify the presence of soft tissue pathology within 
the forefoot using US and patterns of foot-shoe interface pressures in a large cohort of patients 
with RA at two time points. Primarily we have observed that peak plantar pressures measured at 
the foot-shoe interface, are most likely to occur in the medial aspect of the forefoot (confirmed at 
both time points). By contrast, US detectable soft tissue pathology, forefoot bursal hypertrophy 
(confirmed at both time points) and MTP joint synovial hypertrophy (confirmed at twelve 
months) are most likely to be present in the lateral aspect of the forefoot. Additionally, we have 
observed that in this patient group the location of US detectable forefoot soft tissue pathology 
and location of peak foot-shoe interface pressures vary substantially over time.  
 
Our findings are thus important as it is our observation that, in clinical practice, the assessment 
of foot-shoe interface pressures for patients who have RA is increasing. In this patient group, 
clinical strategies to offload peak pressures over time may therefore require additional 
information, such as US imaging to prevent overloading of potential current soft tissue 
inflammation that may not be detected clinically [7, 29, 30]. 
 
Previously in RA participants peak plantar pressures have been investigated against radiological 
erosion scores. In a small group (N=16) of RA participants with established disease (mean 13.0 
years) significant associations between erosion scores in the lateral MTP joints (3rd to 5th) and 
peak pressure under 3rd to 5th MTP joints were reported [15]. Others categorised RA participants 
with established disease, but in remission, (N=50), into high and low forefoot erosion scores and 
found significantly higher forefoot peak pressures occurring in the high erosion group [11]. The 
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latter authors also reported that the highest pressure values were under the 5th MTP joint [11].  
Interestingly, in a larger group (N=62) of RA participants, with established disease (mean 8 years) 
and high frequency of foot symptoms (89%), significant associations were found between  
erosion scores and peak pressures at MTP joints 1 and 4 [13]. It is however difficult to directly 
compare these results with our findings as each investigation used barefoot pedobarographic 
systems to record foot pressures, used different erosion scores and all were cross sectional. 
 
The presence of forefoot erosion is indicative of prevalent foot disease and in the present study 
erosions were predominantly evident within the lateral aspect of the forefoot. It was also found 
that half of our participants had stable unchanging MTP joint synovial hypertrophy and forefoot 
bursal hypertrophy.  By contrast, for half of the cohort we found that the presence in status of 
MTP joint synovial hypertrophy and forefoot bursal hypertrophy varied substantially over the 
twelve month period. We have previously hypothesised that this indicates the formation and 
regression of soft tissue pathology within the forefoot is a dynamic process that may be related to 
biomechanical adaptation [8]. 
 
Otter et al. [10] proposed that high plantar pressures observed in RA participants may be 
associated with a pain avoidance strategy related to off-loading the main site of inflammatory 
pain such as MTP joint synovial hypertrophy. In this study analysis, we found no difference in 
the location of peak plantar pressures between the RA and healthy participants although our 
results indicate that RA participants have significantly higher values of peak plantar pressures 
than healthy participants. The latter findings concur with those of other investigators [13, 14, 31]. 
Our evidence that, over time, changes in US detectable soft tissue pathology appear to be out of 
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phase with changes in foot-shoe interface pressures both temporally and spatially does support 
the suggestion that these patients biomechanically adapt their gait away from forefoot pathology. 
However, we only found a negative association between the presence of US detectable pathology 
and peak pressure values in the right foot, lateral segment, at follow up which only demonstrated 
borderline significance. We also have to consider that peak pressures may not be the most 
clinically useful variable to focus on in this patient population. Further prospective research 
utilising investigation of other foot pressure variables, such as duration of peak pressure, 
pressure-time integrals and centre of pressure relative to forefoot soft tissue pathology and 
patient reported foot symptoms would be useful to determine optimal clinical assessment 
protocols. 
 
It is inevitable that the heterogenous nature of the RA cohort in this study leads to the complexity 
of changes associated with foot status. Indeed the DAS-28 scores over the twelve month period 
indicate a high level of active disease within the cohort, although treatment appears stable. It was 
notable that disease status, measured by ESR, CRP, well-being and DAS-28, was also 
substantially variable over the 12 months. These findings are consistent with the well 
documented variability of RA disease over time [32-34]. 
 
Given the temporal variability of RA disease over time it is surprising that there is a lack of 
longitudinal data related to measurement of plantar foot pressures in RA. Mostly what is known 
is attributable to cross-sectional analytical data [10, 13, 24, 35]. There is even less available 
evidence that investigates foot-shoe interface pressures over time with most attempts at 
longitudinal investigation in this population using barefoot pedobarographic assessment [12, 13, 
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15].  A possible explanation is that measurement of foot-shoe interface pressures is highly 
dependent on the shoe condition and therefore tight control over confounding factors such as 
footwear and activity is required for interventional studies. Inherent in this however is a 
disconnect in previous research findings and clinical utility of in-shoe foot pressure measurement 
within the RA population. The OMERACT (Outcome Measures in Rheumatology) framework 
incorporates truth, discrimination and feasibility as a filter to aid decisions as to the applicability 
of measures [36]. The literature on plantar foot pressure measurement in RA suggests that the 
methods may be feasible  [2] however, their ability to discriminate in clinical practice has yet to 
be determined. Our aim was therefore to examine the forefoot pathology of patients who had RA 
at two cross sectional time points relevant to their usual daily activities / habits to mimic routine 
clinical practice assessments. It was not feasible to control for footwear over such a long period 
of time and in such a large population, which may be controversial. 
 
As a response to this we performed additional analyses and an analysis of variance to assess the 
confounding influences of footwear. We found that the location of peak foot pressure remained 
predominantly medial in all footwear types. However, at twelve months, for the left foot only, 
those wearing unsuitable shoes had higher peak pressure values. In this study therefore, it is 
possible that for the twelve month left foot data peak pressures for the whole group may be 
inflated.  
 
There are several strengths within this study that include a longitudinal cohort follow up design, 
the large sample size, and that it was a pragmatic clinical study representative of secondary care 
in the UK. A few potential limitations should also be considered. Primarily our sample of 
 22
participants was heterogenous, with established disease and treated within secondary care and 
thus may not be generalizable to all patients with RA. Another potential limitation within this 
study is that we did not include tenosynovitis within our US observations of the forefoot and 
were unable to delineate the soft tissue structures in detail. Arguably this approach may 
underestimate the presence of soft tissue pathology within the forefoot. Such a limitation may be 
rectified using Magnetic Resonance Imaging to delineate the soft tissue structures. 
 
Finally, for pragmatic analysis we categorised the forefoot nominally into either medial or lateral 
segments and also amalgamated the foot pathology data due to low counts in these categories, 
thus caution is required in interpreting this observational data. No further statistical inferences 
could be made from this current analysis and we recommend that future work in this area would 
be of value, particularly in the use of US detectable foot pathology  and interface foot-shoe 
pressure pattern identification and cluster analysis [37]. Ideally, future work could focus on 
whether it is the impact of discrete pathology, such as IM or SM bursal hypertrophy, MTP joint 
synovial hypertrophy or tenosynovitis that may be associated with high plantar forefoot pressures 
or whether there is an ‘optimal level’ of forefoot pathology that impacts on plantar foot pressures. 
 
 
Conclusion 
We have observed that there are considerable variations in the presence and location of US 
detectable soft tissue forefoot pathology and patterns of foot-shoe interface pressures over time 
in a large cohort of participants who have RA. We also noted that, in patients with RA, the 
changes in US detectable soft tissue forefoot pathology may be out of phase with the location 
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and values of peak interface foot-shoe pressures. This implies that, in this patient group, clinical 
strategies to offload observed peak pressures, measured at the foot-shoe interface, over time may 
require additional information, such as US imaging to prevent overloading of existent soft tissue 
inflammation. 
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Figures 
Figure 1.  Diagramatic representation of the division of the forefoot into medial and lateral 
pathology. 
Legend: M=metatarsal head; IM=intermetatarsal space; SM=sub-metatarsal area. 
 
Figure 2. Clinical foot characteristics of the RA participants at baseline and 12 months. 
 
Figure 3. Foot joint characteristics of the RA participants at baseline and 12 months. 
 
Figure 4. The most common pattern of foot pressure seen in one RA participant’s left foot 
pressure-map. 
Legend: LA=left lateral forefoot segment; LB= left medial forefoot segment; LC=left midfoot 
lateral segment; LD=left medial midfoot segment; LE=left lateral rearfoot segment; LF=left 
medial rearfoot segment. 
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Tables 
 
Table 1. Demographic and clinical characteristics of the RA participants at baseline and 12 
months (N=114). 
 Baseline 
Mean (±SD) 
12 months 
Mean (±SD) 
Raw Change 
Mean (±SD) 
PSC  
Up 
PSC  
Down 
PSC  
No Change 
Weight (kg) 73.3 (15.5) 73.2 (15.4) - 0.1 (4.3) 56 (49%) 57 (50%) 1 (1%) 
Wellbeing (VAS) 40.1 (23.8) 36.2 (22.8) - 3.3 (25.8) 56 (49%) 56 (49%) 2 (2%) 
ESR (mm/hour) 22.9 (18.6) 24.6 (20.3) 1.8 (16.9) *47 (41%) 53 (47%) 6 (5%) 
CRP (mg/litre) 12.4 (19.5) 14.8 (25.0) 2.9 (29.1) *50 (44%) 39 (34%) 12 (10%) 
DAS-28 3.9 (1.3) 4.1 (1.4) 0.2 (1.8) *35 (31%) 25 (22%) 17 (15%) 
LFISIF (x/21) 10.6 (4.9) 10.3 (4.8) - 0.4 (3.3) 44 (39%) 53 (47%) 17 (15%) 
LFISAP (x/30) 16.5 (9.5) 16.6 (9.7) - 0.1 (5.7) *53 (47%) 43 (38%) 17 (15%) 
Key:*ESR 8 missing data; CRP 13 missing data; DAS-28 37 missing data; LFISAP 1 missing data. 
Legend: PSC=person specific change n(%); VAS = visual analog score; ESR = Erythrocyte sedimentation rate; 
CRP=C-reactive proteins; DAS-28 = 28 joint disease activity score; LFISIF = Leeds Foot Impact Score, 
impairment/footwear subscale; LFISAP = Leeds Foot Impact Score, activity participation limitation subscale. 
 
 
Table 2. Foot pressure characteristics of the RA participants compared to the control 
group at baseline. 
 RA 
Mean (SD) 
Control 
Mean (SD) 
Students t-test 
(95% CIs) 
Left peak pressure (kPa)* 559.1 (281.6) 460.9 (146.0) 
t=2.330, p=0.021 
(14.96-181.45) 
Right peak pressure (kPa)* 581.5 (298.0) 449.5 (167.8) 
t=2.931, p=0.004 
(43.0-220.9) 
Key: *Denotes significance at p<0.05 
 
 
 
Table 3. Foot pressure characteristics of the RA participants at baseline and 12 months. 
 Baseline 
Mean (SD) 
12 months 
Mean (SD) 
Students t-test 
(95% CIs) 
PSC 
increase 
PSC 
decrease 
Left peak 
pressure (kPa) 
559.1 (281.6) 565.1 (291.3) 
t=-0.180, p=0.857 
(-72.6-60.5) 
54 (47%) 60 (53%) 
Right peak 
pressure (kPa) 
581.5 (298.0) 582.3 (396.7) 
t=-0.020, p=0.984 
(-84.7-83.0) 
53 (47%) 61 (54%) 
Legend: PSC=person specific change n(%) 
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Table 4. Location of forefoot pressures in the RA participants(n (%)) at baseline and 
twelve months. 
 
 
 
 
 
 
 
 
 
 
 
Table 5. The presence of person specific(n) stable peak pressure location over 12 months 
for the RA participants.  
Peak pressure location Left Right 
Stable presence lateral A 21 7 
Stable  presence medial B 13 54 
Stable presence C,D,E,F 5 8 
Total stable peak pressure 39 69 
Percentage of cohort 34% 61% 
 
 
Table 6. Location of forefoot pathology in the RA participants(n (%)) at baseline and 
twelve months. 
 
Legend: SynHy: MTP joint synovial hypertrophy; BurHy: Forefoot bursal hypertrophy. 
 Forefoot Midfoot Rearfoot 
 Lateral 
A 
Medial 
B 
Lateral 
C 
Medial 
D 
Lateral 
E 
Medial 
F 
Baseline       
Left  
Right 
37 (33%) 
20 (18%) 
63 (55%) 
70 (61%) 
0 
2 (2%) 
0 
1 (1%) 
2 (2%) 
5 (4%) 
12 (10%) 
16 (14%) 
Twelve Months       
Left               
Right 
37 (33%) 
24 (21%) 
56 (49%) 
72 (63%) 
1 (1%) 
1 (1%) 
0 
0 
7 (6%) 
4 (4%) 
13 (11%) 
13 (11%) 
Pathology Lateral 
dominance 
Medial 
dominance 
Equally 
distributed 
No 
pathology 
Baseline 
Left SynHy      
Right 
37 (33%) 
31 (27%) 
19 (17%) 
25 (22%) 
15 (13%) 
10 (9%) 
43 (38%) 
48 (42%) 
Left              Erosion  
Right 
94 (83%) 
88 (77%) 
1 (1%) 
2 (2%) 
6 (5%) 
6 (5%) 
11 (10%) 
18 (16%) 
Left              BurHy    
Right 
58 (51%) 
56 (49%) 
18 (16%) 
13 (11%) 
20 (18%) 
27 (24%) 
18 (16%) 
18 (16%) 
Twelve Months 
Left              SynHy   
Right 
15 (13%) 
19 (17%) 
34 (30%) 
26 (23%) 
7 (6%) 
14 (12%) 
58 (51%) 
55 (48%) 
Left              Erosion  
Right 
96 (84%) 
89 (78%) 
1 (1%) 
1 (1%) 
11 (10%) 
14 (12%) 
5 (4%) 
10 (9%) 
Left              BurHy   
Right 
61 (54%) 
63 (55%) 
7(6%) 
14 (12%) 
32 (28%) 
22 (19%) 
14 (12%) 
15 (13%) 
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Table 7. The presence of person specific(n) stable forefoot pathology over 12 months for the 
RA participants. 
 
MTP joint synovial 
hypertrophy 
MTP joint  
erosion 
Forefoot bursal 
hypertrophy 
 Left Right Left Right Left Right 
Stable pathology 
presence, lateral 10 7 81 70 37 35 
Stable pathology 
presence, medial 10 10 0 0 1 4 
Stable absence of 
pathology 28 26 2 2 4 4 
Stable equal distribution 
of pathology 1 3 1 0 12 8 
Total stable pathology 49 46 84 72 54 51 
Percentage of cohort 43% 40% 74% 63% 47% 45% 
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